

AHA **2024** HIGHLIGHTS



**MONDAY,
NOVEMBER 25**

7:00 – 8:30 pm EST

Program Overview:

This program covers key clinical trial findings and their implications from AHA 2024. This program is intended for cardiovascular specialists and primary care physicians.

Discussion Topics:

SUMMIT – Tirzepatide in Patients with HFpEF and Obesity

CLEAR – Colchicine and spironolactone in acute MI

BPROAD – What is the optimal BP goal in patients with diabetes and hypertension?

FINE-ARTS – The Latest Data on Finerenone in HFpEF

Learning Objectives:

Following participation in this program, participants will be able to:

- Identify the clinical implications of the new data presented at AHA 2024
- Examine where the data presented may impact clinical practice guidelines
- Apply the latest evidence-based strategies in clinical practice



Register Now!

Visit: www.ccrnmd.com

For inquiries regarding this program, please contact info@ccrnmd.com



Developed by:
 **CCRN**
Collaborative CME and Research Network

SPEAKERS



Milan Gupta

MD, FRCPC, FCCS, CPC(HC)

Assistant Professor, Department of Medicine,
University of Toronto
Medical Director,
Collaborative CME and Research Network
Brampton, ON



Narendra Singh

MD, FRCPC, FCCS, FACC, FAHA

Director, NSC Cardiology
Clinical Assistant Professor,
Medical College of Georgia at
Augusta University and Mercer
University
Atlanta, GA

This program was developed by CCRN and received an unrestricted educational grant from Bayer Canada.